Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: A population-based study

Annals of Surgical Oncology

Volumn 21, Issue 8, 2014, Pages 2636-2641

  Hamza, Samia ^a   Bouvier, Anne Marie ^a   Rollot, Fabien ^a   Lepage, Côme ^a   Faivre, Jean ^a   Bedenne, Laurent ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; RALTITREXED; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

AGE DISTRIBUTION; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BODY WEIGHT DISORDER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COHORT ANALYSIS; COLON CANCER; COLON RESECTION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; GENERAL TOXICITY; GERIATRIC DISORDER; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; SURVIVAL RATE; THROMBOCYTOPENIA; TOXICITY; WEIGHT REDUCTION; ADENOCARCINOMA; CANCER STAGING; CHEMICALLY INDUCED; COLONIC NEOPLASMS; DIGESTIVE SYSTEM DISEASES; FOLLOW UP; FRANCE; HEMATOLOGIC DISEASES; INCIDENCE; MORTALITY; NERVOUS SYSTEM DISEASES; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COLONIC NEOPLASMS; DIGESTIVE SYSTEM DISEASES; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; FRANCE; HEMATOLOGIC DISEASES; HUMANS; INCIDENCE; LEUCOVORIN; MALE; NEOPLASM STAGING; NERVOUS SYSTEM DISEASES; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SURVIVAL RATE;

EID: 84905090157     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3438-z     Document Type: Article

References (20)

1. Colonna M, Bossard N, Remontet L, Grosclaude P. Changes in the risk of death from cancer up to five years after diagnosis in elderly patients: a study of five common cancers. Int J Cancer. 2010;127:924-931.
2. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989;7:1447-1456. (Pubitemid 19245114)
3. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352-358. (Pubitemid 20042739)
4. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351. (Pubitemid 38702845)
5. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091-1097.
6. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, Lopa SH, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009;27:3385-3390.
7. McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E, et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database (abstract). J Clin Oncol. 2009;27:170 s.
8. Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24:4085-4091. (Pubitemid 46622283)
9. Sanoff HK, Carpenter WR, Sturmer T, Goldberg RM, Martin CF, Fine JP, et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 2012;30:2624-2634.
10. Muss HB, Bynum DL. Adjuvant chemotherapy in older patients with stage III colon cancer: an underused lifesaving treatment. J Clin Oncol. 2012;30:2576-2578.
11. World Health Organization. International classification of disease for oncology. 3rd ed. Geneva: World Health Organization; 2000.
12. Sobin L, Wittekin Ch, eds. TNM classification of malignant tumours. 6th ed. New York: Wiley; 2002.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383. (Pubitemid 17055592)
14. Bouvier AM, Launoy G, Lepage C, Faivre J. Trends in the management and survival of digestive tract cancers among patients aged over 80 years. Aliment Pharmacol Ther. 2005;22:233-241. (Pubitemid 41153066)
15. Ayanian JZ, Zaslavsky AM, Fuchs CS, Guadagnoli E, Creech CM, Cress RD, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21:1293-1300. (Pubitemid 46606406)
16. Sundararajan V, Grann VR, Jacobson JS, Ahsan H, Neugut AI. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J. 2001;7:213-218.
17. Kohne CH, Grothey A, Bokemeyer C, Bontke N, Aapro M. Chemotherapy in elderly patients with colorectal cancer. Ann Oncol. 2001;12:435-442. (Pubitemid 32472095)
18. Bouvier AM, Jooste V, Bonnetain F, Cottet V, Bizollon MH, Bernard MP, et al. Adjuvant treatments do not alter the quality of life in elderly patients with colorectal cancer: a population-based study. Cancer. 2008;113:879-886.
19. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst. 1993;85:1580-1584. (Pubitemid 23304686)
20. Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29:3768-3774.